semaglutide select Trial: reduces the risk of MACE by 20% in people with overweight or obesity, pre-existing CVD, and no diabetes. Average weight loss of -9.4% at 51 months Early clinical benefit of semaglutide

10.1038/s41598-024-54555-2 121 ZhaoG.LiX.ZhangY.WangX.DengL.XuJ.et al (2025a)

Research demonstrates that approximately one-third of patients lose less than 0.5% body weight weekly during the first month of intensive behavioral treatment, with the majority of these individuals ultimately failing to achieve clinically meaningful results after six months

In other medical conditions, GLP-1 receptor agonists have been shown to reduce inflammatory cytokines, lower oxidative stress, and improve visceral inflammation

Early intervention restarting a low dose, adjusting diet, or adding coaching prevents small regains from becoming large ones

Primary Cellular Pathways Triple Incretin Receptor Activation Metabolic Regulation GLP3 functions as a triple agonist simultaneously activating GLP-1R, GIPR, and GCGR with distinct potency profiles[1]

Some people may notice improvements within a few weeks, but for others, it might take a couple of months of consistent use to observe noticeable benefits